Document is current
Any future updates will be listed below
-
Authors
Chalopin, Thomas https://orcid.org/0000-0002-9833-3115
Cellerin, Elise
Demarquette, Hélène
Pieragostini, Andréa
Sonntag, Cécile
Jaquet, Caroline
De Wyngaert, Zoé https://orcid.org/0000-0001-9463-2823
Rumpler, Anne
Roussel, Murielle
Labouré, Gaelle
Morel, Véronique
Vincent, Laure https://orcid.org/0000-0001-5904-1286
Salle, Valéry
Cazaubiel, Titouan
Bobin, Arthur
Schavgoulidze, Anaïs https://orcid.org/0000-0002-5526-4279
Corre, Jill https://orcid.org/0000-0003-1580-6106
Leleu, Xavier https://orcid.org/0000-0002-9822-4170
Manier, Salomon
- License Information
-
More Information
Article History
Received: 7 June 2025
Revised: 5 August 2025
Accepted: 5 September 2025
First Online: 21 October 2025
Competing interests
: TC: Consultant/Advisory Boards: BMS, Takeda, Janssen, GSK, Griffols, Amgen, Sanofi, Pfizer, Stemline. XL has received consultancy, honoraria and travel fees from Sanofi, Janssen-Cilag, Kite/Gilead, Amgen, Novartis, Takeda, Pfizer, Oncopeptide, AbbVie, GSK and Bristol Myers Squibb. AB received consultancy and honoraria from Sanofi, Janssen-Cilag. The other authors declare no competing interests.
: All centers obtained institutional review board approval, which granted a waiver of patient consent, and the study was conducted in accordance with the Declaration of Helsinki. This study was approved by the local Ethics Committees, in compliance with applicable ethical standards (n° 2024 053 and CNIL n° 18355189).
